RETINITIS PIGMENTOSA 1
Replimune’s Shares Plunge After FDA Rejects Melanoma Drug Application
Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop
Actionable Insights Powered by AI
Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop